全文获取类型
收费全文 | 1654篇 |
免费 | 102篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 29篇 |
妇产科学 | 19篇 |
基础医学 | 105篇 |
口腔科学 | 17篇 |
临床医学 | 309篇 |
内科学 | 609篇 |
皮肤病学 | 15篇 |
神经病学 | 134篇 |
特种医学 | 11篇 |
外科学 | 81篇 |
综合类 | 104篇 |
预防医学 | 32篇 |
眼科学 | 6篇 |
药学 | 240篇 |
1篇 | |
中国医学 | 51篇 |
肿瘤学 | 17篇 |
出版年
2024年 | 2篇 |
2023年 | 34篇 |
2022年 | 58篇 |
2021年 | 108篇 |
2020年 | 117篇 |
2019年 | 96篇 |
2018年 | 80篇 |
2017年 | 55篇 |
2016年 | 59篇 |
2015年 | 52篇 |
2014年 | 98篇 |
2013年 | 148篇 |
2012年 | 76篇 |
2011年 | 66篇 |
2010年 | 42篇 |
2009年 | 54篇 |
2008年 | 37篇 |
2007年 | 60篇 |
2006年 | 35篇 |
2005年 | 50篇 |
2004年 | 49篇 |
2003年 | 37篇 |
2002年 | 27篇 |
2001年 | 29篇 |
2000年 | 21篇 |
1999年 | 18篇 |
1998年 | 20篇 |
1997年 | 32篇 |
1996年 | 24篇 |
1995年 | 15篇 |
1994年 | 21篇 |
1993年 | 13篇 |
1992年 | 15篇 |
1991年 | 16篇 |
1990年 | 16篇 |
1989年 | 15篇 |
1988年 | 9篇 |
1987年 | 10篇 |
1986年 | 7篇 |
1985年 | 9篇 |
1984年 | 10篇 |
1983年 | 10篇 |
1982年 | 10篇 |
1981年 | 5篇 |
1980年 | 3篇 |
1979年 | 4篇 |
1978年 | 4篇 |
1976年 | 2篇 |
1973年 | 1篇 |
1906年 | 1篇 |
排序方式: 共有1782条查询结果,搜索用时 15 毫秒
1.
2.
Ramya C. Mosarla Muthiah Vaduganathan Arman Qamar Javid Moslehi Gregory Piazza Robert P. Giugliano 《Journal of the American College of Cardiology》2019,73(11):1336-1349
Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer. 相似文献
3.
4.
目的: 评估液相色谱-电喷雾串联质谱(LC-ESI-MS/MS)分析人全血中环孢素的基质效应,并探究其发生机理。方法: 全血裂解物的蛋白沉淀上清液用作全血基质。分别用乙腈水溶液和全血基质配制等浓度环孢素A(CyA)、环孢素C(CyC)的质控样品。分别在添加H+、NH4+和Na+的流动相中,用LC-ESI-MS/MS的MRM模式检测质控样品中CyA,CyC的[M+H]+、[M+NH4]+和[M+Na]+(M=CyA,CyC)峰面积,以其计算基质效应因子;用MS Scan模式检查质控样品中CyA、CyC色谱流出峰的质谱离子组成情况,用于判断基质效应原因。结果: 在添加H+、NH4+和Na+的流动相中,全血基质中CyA、CyC基质效应因子分别为-76.6%~-54.0%、-86.0%~-55.3%和-42.8%~-34.1%。在加H+、加NH4+流动相中,标准液加全血基质的CyA、CyC色谱峰的质谱中出现丰度很高的[M+Na]+和[M+K]+,在加Na+流动相中它们出现丰度很高的[M+K]+,而对应的定量离子[M+H]+、[M+NH4]+或[M+Na]+的丰度显著降低。结论: 全血基质对环孢素的LC-ESI-MS/MS分析产生明显的基质效应,其原因与基质中Na+、K+同添加在流动相中用于辅助电离的H+、NH4+或Na+竞争与环孢素加合,导致定量目标加合离子丰度显著降低有关。 相似文献
5.
目的 评价溴敌隆防制家栖鼠的效果。方法 实验室有选择适口性试验 ,现场灭家栖鼠效果考核。结果 在有选择的摄食试验条件下 ,0 .0 0 5 %溴敌隆大米毒饵对褐家鼠和黄胸鼠的毒杀率达 10 0 %和 94 .4 4 % ,摄食系数分别为 0 .6 3和 0 .5 4 ,致死剂量分别为 9.97(0 .0 6~ 2 4 .6 9)和 7.93(5~ 17.6 1)mg/kg。现场灭家栖鼠试验 ,灭鼠率达 86 .4 3%。结论 溴敌隆对家栖鼠毒效髙 ,适口性好 ,具有较好的防制效果 相似文献
6.
β2-glycoprotein-I (β2GPI) is a phospholipid-binding plasma protein that consists of five homologous domains. Domain V is distinguished from others by bearing a positively charged lysine cluster and hydrophobic extra C-terminal loop. β2GPI has been known as a natural anticoagulant regulator. β2GPI exerts anticoagulant activity by inhibition of phospholipid-dependent coagulation reactions such as prothrombinase, tenase, and factor XII activation. It also binds factor XI and inhibits its activation. On the other hand, β2GPI inhibits anticoagulant activity of activated protein C. According to the data from knockout mice, β2GPI may contribute to thrombin generation in vivo. Phospholipid-bound β2GPI is one of the major target antigens for antiphospholipid antibodies present in patients with antiphospholipid syndrome (APS). Binding of pathogenic anti-β2GPI antibodies increases the affinity of β2GPI to the cell surface and disrupts the coagulation/fibrinolysis balance on the cell surface. These pathogenic antibodies activate endothelial cells via signal transduction events in the presence of β2GPI. Impaired fibrinolysis has been reported in patients with APS. Using a newly developed chromogenic assay, we demonstrated lower activity of intrinsic fibrinolysis in euglobulin fractions from APS patients. Addition of monoclonal anti-β2GPI antibodies with β2GPI also decreased fibrinolytic activity in this assay system. β2GPI is proteolytically cleaved by plasmin in domain V (nicked β2GPI) and becomes unable to bind to phospholipids, reducing antigenicity against antiphospholipid antibodies. This cleavage occurs in patients with increased fibrinolysis turnover. Nicked β2GPI binds to plasminogen and suppresses plasmin generation in the presence of fibrin, plasminogen, and tissue plasminogen activator (tPA). Thus, nicked β2GPI plays a role in the extrinsic fibrinolysis via a negative feedback pathway loop. 相似文献
7.
8.
R. -M. Jolidon MD H. Knecht L. Humair A. de Torrente 《Journal of molecular medicine (Berlin, Germany)》1991,69(8):340-344
Summary A young man who had suffered several episodes of deep-vein thrombosis of the legs since the age of 20 had a myocardial infarction at the age of 33, at which time both a prolonged partial thromboplastin time (PTT), compatible with a lupus anticoagulant (LA), and decreased fibrinolytic capacity (FC) were found.His sister presented with deep-vein thrombosis of a leg and subsequent pulmonary embolism when she was 18 years old. She had a miscarriage three years later and developed a hemolytic-uremic syndrome at the age of 35. The PT and FC were normal. Laboratory investigations of the parents revealed positive antinuclear antibodies in the mother's serum but no anomaly in the father.This study suggests a familial tendency to develop autoimmune disorders associated with LA and thromboembolic complications related to decreased FC. 相似文献
9.
10.
Soulika AM Khan MM Hattori T Bowen FW Richardson BA Hack CE Sahu A Edmunds LH Lambris JD 《Clinical immunology (Orlando, Fla.)》2000,96(3):212-221
Complement activation products are major components of the inflammatory response induced by cardiac surgery and cardiopulmonary bypass which contribute to postoperative organ dysfunction, fluid accumulation, and morbidity. Activation of the complement system occurs during extracorporeal circulation, during reperfusion of ischemic tissue, and after the formation of heparin-protamine complexes. In this study we examine the efficacy of Compstatin, a recently discovered peptide inhibitor of complement, in preventing heparin/protamine-induced complement activation in baboons. The study was performed in baboons because Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans); Compstatin inhibits only the activation of primates' complement system. After testing various doses and administration regimens, Compstatin produced complete inhibition at a total dose of 21 mg/kg when given as a combination of bolus injection and infusion. Compstatin completely inhibited in vivo heparin/protamine-induced complement activation without adverse effects on heart rate or systemic arterial, central venous, and pulmonary arterial pressures. This study indicates that Compstatin is a safe and effective complement inhibitor that has the potential to prevent complement activation during and after clinical cardiac surgery. Furthermore, Compstatin can serve as the prototype for designing an orally administrated drug. 相似文献